'We're good to go': MyoKar­dia clinch­es cru­cial PhI­II win, boost­ing ge­net­ic ap­proach to car­dio R&D

MyoKar­dia said its lead drug has de­liv­ered a clean sweep in a Phase III tri­al, val­i­dat­ing its ground­break­ing idea for bring­ing pre­ci­sion med­i­cine to car­diomy­opathies and paving the way for an NDA fil­ing ear­ly next year.

Con­sis­ten­cy was the theme trumped by the top team in a con­fer­ence call, where Marc Sem­i­gran, SVP of med­ical sci­ences, of­fered some more num­bers on the pri­ma­ry end­point and a slate of sec­ondary end­points be­yond the stel­lar p-val­ues in the re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER